{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-013989","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.542731+00:00","generated_at":"2026-05-15T00:55:06.610799+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Genprex granted Israel patent for Reqorsa gene therapy with PD-1 antibodies","bullets":["Israel Patent Office granted patent covering Reqorsa (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment.","Patent expands IP portfolio previously granted in U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore, and Europe.","Reqorsa is initially being developed for lung cancer; preclinical data shows complementarity with targeted drugs and immunotherapies.","Israel lung cancer cases rose 33% in a decade; 200 new cases/month; leading cancer death cause in 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-013989","json":"https://secwatch.observer/filing/0001437749-26-013989.json","markdown":"https://secwatch.observer/filing/0001437749-26-013989.md","text":"https://secwatch.observer/filing/0001437749-26-013989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926013989/0001437749-26-013989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926013989/gnpx20260429_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:55:06.610799+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}